,CB1R-NMDAR

Irene Reyes-Resina1,2,3, Jaume Lillo2,3,4, Iu Raïch1,2,3

  • 1Department of Biochemistry and Physiology, School of Pharmacy and Food Sciences, Universitat de Barcelona, 08028 Barcelona, Spain.

概括

帕金森病涉及NMDA受体 (NMDAR) 和大麻素受体1 (CB1R) 的变化. 这项研究揭示了α-synuclein破坏CB1R-NMDAR复合体,表明它们是帕金森病的潜在治疗点.